U.S. markets closed

Meridian Bioscience, Inc. (VIVO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.50+0.99 (+6.38%)
At close: 4:00PM EDT

16.58 +0.08 (0.48%)
After hours: 4:26PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close15.51
Open15.57
Bid15.12 x 1400
Ask16.60 x 3100
Day's Range15.54 - 16.56
52 Week Range5.51 - 26.58
Volume486,450
Avg. Volume743,184
Market Cap707.233M
Beta (5Y Monthly)0.73
PE Ratio (TTM)16.16
EPS (TTM)1.02
Earnings DateAug 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateFeb 01, 2019
1y Target Est26.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-59% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Meridian Bioscience (NASDAQ:VIVO) Share Price Has Gained 62% And Shareholders Are Hoping For More
    Simply Wall St.

    The Meridian Bioscience (NASDAQ:VIVO) Share Price Has Gained 62% And Shareholders Are Hoping For More

    While Meridian Bioscience, Inc. (NASDAQ:VIVO) shareholders are probably generally happy, the stock hasn't had...

  • GlobeNewswire

    Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples

    CINCINNATI, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is pleased to announce the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva. Coronavirus-neutralizing antibodies primarily target the trimeric spike (S) glycoprotein on the viral surface that mediates entry into the host cell. This antibody pair binds to recombinant SARS-CoV-2 trimeric spike protein. Intentionally designed and screened for the development of rapid saliva antigen tests, these antibodies recognize a linear epitope of the SARS-CoV-S1 trimeric protein. The antibody pair is the first-of-its-kind, having sensitivity down to picograms per milliliter as measured by ELISA. Further, the antibody pair is highly specific to the SARS-CoV-2 trimeric spike protein and does not cross react with other coronaviruses, such as SARS-CoV, HCoV-229F, HCoV-HKUI, HCoV-NL63 and HCoV-OC43.“Meridian has already enabled the manufacture of millions of COVID-19 assays dating back to the early days of the pandemic. This new antibody pair reflects Meridian’s on-going commitment to be the leading partner to the diagnostics industry through continuous innovation, enhancing the tools R&D teams have to fight this global pandemic,” said Todd Howren, Ph.D., Vice President Global Sales for Meridian Bioscience, Life Science Division. “A rapid COVID-19 antigen assay from saliva, which does not sacrifice sensitivity, is now possible due to this novel antibody pair.”“Accelerated scale-up efforts of this antibody pair are now in progress and Meridian is excited to partner with our IVD customers to bring rapid antigen COVID-19 assays to market” said Lourdes Weltzien, Ph.D., Executive Vice President for Meridian Bioscience, Life Science Division.Meridian is committed to supplying innovative solutions to the diagnostic industry during times of a pandemic health crisis. For more information on partnering with Meridian Bioscience please visit meridianlifescience.com or contact: lourdes.weltzien@meridianbioscience.com.About Meridian Bioscience, Inc.Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.Contact: Charlie Wood Vice President – Investor Relations Meridian Bioscience, Inc. Phone: +1 513.271.3700 Email: mbi@meridianbioscience.com

  • GlobeNewswire

    Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference

    CINCINNATI, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET. To access the live webcast, go the Events & Presentations section of the Company’s Investor Relations website at https://investor.meridianbioscience.com/. Participants should register several minutes in advance of the event’s start time by following the link provided for the event.About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.Contact: Charlie Wood Vice President – Investor Relations Meridian Bioscience, Inc. Phone: +1 513.271.3700 Email: mbi@meridianbioscience.com